



Workshop program

Location: Universität Witten/Herdecke, Richtersaal, Stockumer Straße 10, 48543 Witten

Thursday, November 28

Chair: Florian Kreppel, Witten

Opening remarks – Florian Kreppel

- 17:00 Karim Benihoud, Université Paris-Sud, France (invited)
Insights into adenovirus vectorology and its use for vaccination and virotherapy
- 18:00 Nicolas Mach, Witten
Evaluation of transduction efficiencies and oncolytic potency of reporter gene-tagged human adenoviruses on breast cancer cells
- 18:20 Jian Gao, Witten
MicroRNA expression in concert with stable expression of a chimeric virus capsid protein for transient virus modification without genome alteration
- 18:40-19:00 Philip Podschwadt, Bochum
Identifying immunosuppressive sequences in retroviral envelope proteins
- 20:00 Get-together with dinner at Café del Sol, Witten

Friday, November 29

Chair: Armin Baiker, München

- 08:30 Ian Johnston, Miltenyi Biotech, Germany (invited)
Cell and gene therapy – coming of age
- 09:30 Juliane Kuklik, Boehringer Ingelheim, Biberach
Site-specific AAV2 modification for retargeting to tumor tissues
- 09:50 Desiree Schütz, Ulm
The future of gene therapy: EF-C peptide nanofibrils as potent transduction enhancers
- 10:10 Stefanie Schmeiser, Köln
Die neue Gentechnik-Sicherheitsverordnung
- 10:30 Pause



Chair: Claudia Hagedorn, Witten

10:40 Jonas Scholz, Witten
Generation and characterization of an adenovirus-based miRNA expression system

11:00 Zina Sarif, Berlin
Silencing mcl-1 enhances the proapoptotic effects of Vemurafenib in melanoma cells

11:20 Malik Aydin, Wuppertal
Towards understanding of regulatory networks influencing the exacerbation of wheeze and asthma

11:40 Mittagspause

Chair: Anja Ehrhardt, Witten

13:00 Teresa Krabbe, TU Munich, Germany (invited)
Adoptive T-cell therapy as a complementary immunotherapeutic for the chimeric oncolytic virus platform VSV-NDV

From bench to bedside to stock market with VSV-NDV? - A real-life pitch deck

13:35 Orsolya Hamusics, Braunschweig
Development of a Herpes Simplex virus production process

13:55 Melanie Spahn, Braunschweig
Development of a downstream process for the manufacturing of a Herpes Simplex-based oncolytic virus

14:15 Pause

Chair: Franziska Jönsson, Witten

14:25 Sofia Klemm, Mainz
The Myb-related restriction factor MYPOP as novel tumor suppressor

14:45 Oskar Bunz
JAML – a new potential adenovirus receptor from the immunoglobulin superfamily expressed on gamma delta T-cells

15:05 Kemal Mese
Broad-spectrum antiviral function of magnesium chloride modified heparin

15:25 Concluding remarks – Florian Kreppel